Skip to main content

Advertisement

SpringerLink
Log in

Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

ET-743 (Yondelis®, trabectedin) and PM00104 (Zalypsis®) are marine derived compounds which demonstrate anti-tumor activity. The present study was performed to elucidate the relationship between the expression of ABCB1/MDR1 and ABCC1/MRP1 with resistance to either ET-743 or PM00104.

Methods

We evaluate the association between expression of Pgp1, MRP1, and BCRP proteins and ET-743 or PM00104 resistance in a large panel of multi-drug resistant cell lines derived from histologically unrelated human tumors that were selected with paclitaxel, doxorubicin, cisplatin, mitoxantrane, or gemcitibine.

Results

Paclitaxel selected resistantcell lines expressed high levels of ABCB1 (but not ABCC1 or ABCG2/BCRP) did not demonstrate cross-resistance to either ET-743 or PM00104. In contrast, the doxorubicin selected resistant cell lines also expressed high level of ABCB1 (but not ABCC1 or ABCG2) but did demonstrate significant cross-resistance to both ET-743 and PM00104. The paclitaxel selected cell lines demonstrated cross-resistance to doxorubicin, vincristine, and mitoxantrane, while most of the above doxorubicin selected cell lines demonstrated cross-resistance to paclitaxel and vincristine, but not to mitoxantrane. On the contrary, cisplatin and gemcitabine selected cell lines demonstrated no cross-resistance to paclitaxel, doxorubicin, ET-743, or PM00104. siRNA down-regulation of ABCB1 expression in doxorubicin selected cell lines caused partial sensitization to both doxorubicin and paclitaxel but not to either ET-743 or PM00104.

Conclusions

These results indicate that cell lines selected for resistance to either paclitaxel or doxorubicin are cross-resistant to many other drugs and that, for these cell lines, ABCB1 over-expression is not necessary to confer resistance to either ET-743 or PM00104. Diversity of cross-resistance observed in these multi-drug resistant cell lines are associated with the initial drug used for in vitro selection, but not to ABCB1 expression. This study suggests that a common molecular pathway other than ABCB1 may be involved in the mechanism of resistance to ET-743 or PM00104.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidalgo M (2003) Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol 14:1607–1615

    Article  PubMed  CAS  Google Scholar 

  2. Beumer JH, Buckle T, Ouwehand M, Franke NE, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O (2007) Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest New Drugs 25:1–7

    Article  PubMed  CAS  Google Scholar 

  3. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942

    PubMed  CAS  Google Scholar 

  4. Carter NJ, Keam SJ (2007) Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67:2257–2276

    Article  PubMed  CAS  Google Scholar 

  5. Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB (2006) Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 58:384–395

    Article  PubMed  CAS  Google Scholar 

  6. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D’Incalci M (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92:583–588

    Article  PubMed  CAS  Google Scholar 

  7. Duan Z, Foster R, Brakora KA, Yusuf RZ, Seiden MV (2006) GBP1 overexpression is associated with a paclitaxel resistance phenotype. Cancer Chemother Pharmacol 57:25–33

    Article  PubMed  CAS  Google Scholar 

  8. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV (2005) Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 55:277–285

    Article  PubMed  CAS  Google Scholar 

  9. Erba E, Bergamaschi D, Bassano L, Ronzoni S, Di Liberti G, Muradore I, Vignati S, Faircloth G, Jimeno J, D’Incalci M (2000) Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer 82:1732–1739

    Article  PubMed  CAS  Google Scholar 

  10. Faircloth G, Cuevas C (2006) Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 43:363–379

    PubMed  CAS  Google Scholar 

  11. Feller N, Broxterman HJ, Wahrer DC, Pinedo HM (1995) ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 368:385–388

    Article  PubMed  CAS  Google Scholar 

  12. Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD (2005) Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23:5484–5492

    Article  PubMed  CAS  Google Scholar 

  13. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831

    Article  PubMed  CAS  Google Scholar 

  14. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S (2006) Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 66:8155–8162

    Article  PubMed  CAS  Google Scholar 

  15. Kanzaki A, Takebayashi Y, Ren XQ, Miyashita H, Mori S, Akiyama S, Pommier Y (2002) Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 1:1327–1334

    PubMed  CAS  Google Scholar 

  16. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME (2007) A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 97:1618–1624

    Article  PubMed  CAS  Google Scholar 

  17. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS (2005) Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23:576–584

    Article  PubMed  CAS  Google Scholar 

  18. Lourda M, Trougakos IP, Gonos ES (2007) Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein. J Int J Cancer 120:611–622

    Article  CAS  Google Scholar 

  19. Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger CM, Astolfi A, Bagnati R, D’Incalci M, Picci P, Scotlandi K (2005) The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing’s sarcoma cell line, TC-71. Int J Oncol 27:1605–1616

    PubMed  CAS  Google Scholar 

  20. Rinehart KL (2000) Antitumor compounds from tunicates. Med Res Rev 20:1–27

    Article  PubMed  CAS  Google Scholar 

  21. Rinehart KL, Holt TG, Fregeau NL, Keifer PA, Wilson GR, Perun TJ Jr, Sakai R, Thompson AG, Stroh JG, Shield LS et al (1990) Bioactive compounds from aquatic and terrestrial sources. J Nat Prod 53:771–792

    Article  PubMed  CAS  Google Scholar 

  22. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA (1999) Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91:429–433

    Article  PubMed  CAS  Google Scholar 

  23. Schoffski P, Wolter P, Clement P, Sciot R, De Wever I, Wozniak A, Stefan C, Dumez H (2007) Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 3:381–392

    Article  PubMed  Google Scholar 

  24. See HT, Kavanagh JJ, Hu W, Bast RC (2003) Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 13:701–734

    Article  PubMed  CAS  Google Scholar 

  25. Shao L, Kasanov J, Hornicek FJ, Morii T, Fondren G, Weissbach L (2003) Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. Biochem Pharmacol 66:2381–2395

    Article  PubMed  CAS  Google Scholar 

  26. Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, Larsen AK (2007) Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 104:13062–13067

    Article  PubMed  Google Scholar 

  27. Valoti G, Nicoletti MI, Pellegrino A, Jimeno J, Hendriks H, D’Incalci M, Faircloth G, Giavazzi R (1998) Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4:1977–1983

    PubMed  CAS  Google Scholar 

  28. Yin J, Aviles P, Lee W, Ly C, Guillen MJ, Munt S, Cuevas C, Faircloth G (2005) Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM00104, a novel antineoplastic agent, in mouse, rat, dog, and human plasma. Rapid Commun Mass Spectrom 19:689–695

    Article  PubMed  Google Scholar 

  29. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1–19

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This project was supported by a Grant from PharmaMar. Dr. Duan is supported, in part, through a grant from Ovarian Cancer Research Foundation (OCRF), and a grant from the National Cancer Institute, NIH (Nanotechnology Platform Partnership), R01-CA119617. Support has also been provided by the Gaetagno and Wechsler funds.

Author information

Authors and Affiliations

  1. Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 100 Blossom St. Jackson 1106, Boston, MA, 02114, USA

    Zhenfeng Duan, Henry J. Mankin & Francis J. Hornicek

  2. Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA

    Edwin Choy

  3. PharmaMar USA, Inc., Cambridge, MA, 02142, USA

    Jose Maria Jimeno & Carmen Del Maria Cuevas

Authors
  1. Zhenfeng Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edwin Choy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose Maria Jimeno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carmen Del Maria Cuevas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henry J. Mankin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francis J. Hornicek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhenfeng Duan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duan, Z., Choy, E., Jimeno, J.M. et al. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol 63, 1121–1129 (2009). https://doi.org/10.1007/s00280-008-0843-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0843-2

Keywords

Search

Navigation